BioCentury | Jan 4, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: December 2017

New Therapeutic Targets and Biomarkers: December 2017 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during December 2017. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Dec 13, 2017
Distillery Therapeutics

Cancer

INDICATION: Breast cancer; ovarian cancer Patient sample and mouse studies suggest inhibiting EGFL6 could help treat breast and ovarian cancers. In tissue samples from ovarian cancer patients, endothelial cell levels of EGFL6 were higher in...
BioCentury | Oct 21, 2013
Clinical News

Parsatuzumab: Development discontinued

...Product: Parsatuzumab (RG7414, RO5490248) Business: Cancer Molecular target: EGF-like-domain multiple 7 (EGFL7) Description: Humanized mAb against EGF-like-domain multiple 7 (EGFL7...
BioCentury | Oct 18, 2013
Financial News

Roche reports 3Q13 sales of new cancer drugs

...it discontinued development of parsatuzumab ( RG7414 ), a mAb against EGFL7-like-domain multiple 7 ( EGFL7...
BioCentury | Nov 17, 2011
Distillery Therapeutics

Indication: Cancer

...suggest inhibiting EGFL7 could help treat cancer. In mice with xenograft breast cancer cells overexpressing Egfl7...
...Next steps could include developing Egfl7 inhibitors and testing the molecules in vivo. RG7414, an anti-EGFL7...
BioCentury | Aug 3, 2009
Clinical News

RG7414: Phase Ia started

...Roche (SIX:ROG; OTCQX:RHHBY), Basel, Switzerland Product: RG7414 Business: Cancer Molecular target: EGF-like-domain multiple 7 (EGFL7) Description: Anti-EGF-like-domain multiple 7 (EGFL7...
BioCentury | Dec 20, 1999
Company News

Hyseq Inc. other research news

HYSQ published in Genomics that EGFL6, which encodes a secreted protein, is selectively expressed in lung tumor tissue but not in healthy lung tissue. HYSQ said the gene could be used to develop lung cancer...
Items per page:
1 - 7 of 7